Idiopathic Pulmonary Fibrosis (IPF) Request More Information Trial Objective The purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI). The study also will determine if stomach reflux or abnormal swallowing are associated with the progression of IPF. Enrollment This trial is active and currently recruiting. Who Can Participate Individuals ages 40-95 who have been diagnosed with IPF may be eligible to participate. Age: 40-95 Gender: Any Gender Estimated Time Commitment 5 visits over a 6-month period, visits are every 3 months Compensation Provided Trial Contact For more information, contact: Cole Waliczek 303.398.2844 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors Boehringer Ingelheim Principal Investigators Jeffrey Swigris, DO, MS + × Jeffrey Swigris, DO, MS Professor Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine View Full Profile Patient Rating 4.9 out of 5 stars Make an Appoinment Request More Information First Name:* Last Name:* Email Address:* Phone:*
Trial Objective The purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI). The study also will determine if stomach reflux or abnormal swallowing are associated with the progression of IPF.